[(2-propoxyethoxy)methyl]benzene | 91764-31-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(2-propoxyethoxy)methyl]benzene
• 英文别名: 1-benzyloxy-2-propoxy-ethane；1-Benzyloxy-2-propoxy-aethan；2-propoxyethoxymethylbenzene
• CAS: 91764-31-7
• 化学式: C₁₂H₁₈O₂
• 分子量: 194.274
• InChiKey: BFAFEPPFYVIYQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  乙二醇单正丙醚 在 乙醚 、 sodium 作用下， 生成 [(2-propoxyethoxy)methyl]benzene
  参考文献：
  名称：

  The Importance of Aesthetics in Body Dysmorphic Disorder

  摘要：

  摘要 假设身体畸形障碍（BDD）患者首先更具 "美感"，这种特质很像音乐感，因人而异。与健康人相比，这将导致他们对更具吸引力的个体产生更大的情感反应，并更加重视外表在身份认同中的重要性。一些 BDD 患者可能具有更强的审美感知能力。这表现在他们接受过艺术和设计方面的教育或培训。其次，BDD 患者的审美标准可能高于其他人群。他们无法达到不切实际的审美标准是 BDD 的核心，导致严重的痛苦和障碍。

  DOI：

  10.1017/s1092852900017922

文献信息

• [EN] SENOTHERAPEUTIC COMPOUND<br/>[FR] COMPOSÉ SÉNOTHÉRAPEUTIQUE
  申请人：BIONEXA S R L

  公开号：WO2022118186A1

  公开（公告）日：2022-06-09

  It is provided a senotherapeutic compound comprising a synthetic derivative of flavones, according to the formula (I), in which at least two of R2-R6 are H, and the remainder are individually selected from: H, OH, R1, OR1, NO2, NH2, NHR1, F, Cl, Br, I, where R1 is a radical.

  提供一种含有黄酮类合成衍生物的治疗化合物，其化学式为(I)，其中R2-R6中至少有两个为H，其余的分别从以下中选择：H，OH，R1，OR1，NO2，NH2，NHR1，F，Cl，Br，I，其中R1是一个基团。
• [EN] USE OF MACROCYCLIC COMPOUNDS IN METHODS OF TREATING CANCER<br/>[FR] UTILISATION DE COMPOSÉS MACROCYCLIQUES DANS DES MÉTHODES DE TRAITEMENT DE CANCER
  申请人：SCORPION THERAPEUTICS INC

  公开号：WO2022098992A1

  公开（公告）日：2022-05-12

  This disclosure provides chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit epidermal growth factor receptor (EGFR, ERBB1) and/or Human epidermal growth factor receptor 2 (HER2, ERBB2). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) EGFR and/or HER2 activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

  本公开提供化合物（例如，化合物或药物可接受的盐，和/或水合物，和/或共晶体，和/或化合物的药物组合物），其抑制表皮生长因子受体（EGFR，ERBB1）和/或人类表皮生长因子受体2（HER2，ERBB2）。这些化合物是有用的，例如，用于治疗某种情况，疾病或障碍，在该情况，疾病或障碍中增加（例如过度）的EGFR和/或HER2激活对该情况，疾病或障碍的病理生理和/或症状和/或进展有贡献的受试者（例如，人类）。本公开还提供包含相同物质的组合物以及使用和制备相同物质的方法。
• In-situ generation of Et3SiBr from BiBr3 and Et3SiH and its use in preparation of dialkyl ethers
  作者：Joginder S. Bajwa、Xinglong Jiang、Joel Slade、Kapa Prasad、Oljan Repič、Thomas J. Blacklock

  DOI：10.1016/s0040-4039(02)01532-0

  日期：2002.9

  The reported BiBr3-Et3SiH catalyzed reductive etherifications of silyl ethers with carbonyl compounds are shown to be catalyzed by the in situ formed Et3SiBr and verified by an independent use of the commercial reagent. As Et3SiBr is moisture sensitive and is not readily available, this in situ generation is still recommended as the method of choice. Utilizing this method, several alcohols were transformed under very mild conditions into dialkyl ethers via their silyl intermediates, such as TES, TBDMS, and TIPS. (C) 2002 Elsevier Science Ltd. All rights reserved.
• Novel Fused Pyrrolocarbazoles
  申请人：Hudkins L. Robert

  公开号：US20070203135A1

  公开（公告）日：2007-08-30

  The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.
• NOVEL FUSED PYRROLOCARBAZOLES
  申请人：Hudkins Robert L.

  公开号：US20090186888A1

  公开（公告）日：2009-07-23

  The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.